JPRN-UMIN000009090招募中4 期
Observational study of paclitaxel with Bevacizumab for advanced or recurrent breast cancer(SBCCSG-28) - Observational study of paclitaxel with Bevacizumab for advanced or recurrent breast cancer(SBCCSG-28)
Saitama Breast Cancer Clinical Study Group (SBCCSG)0 个研究点目标入组 70 人开始时间: 2012年10月12日最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 招募中
- 发起方
- 入组人数
- 70
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •Only treatment with Bevacizumab planned case 4-1.Have hypersensitivity to Bevacizumab 4-2.During pregnancy or lactation 4-3.Patients receiving anticoagulant therapy 4-4.Daily treatment with hight-dose aspirin(>=325mg/day) or non-steroidal anti-inflammatory medications for chronic inflammatory disease 4-5.Bleeding tendency(including significant hemoptysis or pulmonary tumor cavitation and necrosis),(INR>=1.5 within two weeks prior to entry) 4-6.Uncontrolled peptic ucer 4-7.Perforation of gastrointestional tract within one year 4-8.Renal failure to treated,2+ or higher proteinuria within two weeks prior to entry 4-9.Uncontrolled hypertension 4-10.Clinically significant cardiovascular disease(>=Grade2 according to the Common Toxicity Criteria of the National Cancer Institute,version 4), clinically important echocardiographic findigs,or past or current history(within the last one year)of myocardial infarction 4-11.Not appropriate for the study at the physician's assessment
研究者
相似试验
已完成
2 期
A phase II study of Bevacizumab plus Paclitaxel followed by Eribulin maintenance therapy in patients with HER2-negative metastatic breast cancer.HER2-negative metastatic breast cancerJPRN-UMIN000015971Sairtama Breast Cancer Clinical Study Group (SBCCSG)51
已完成
2 期
A phase II study of Paclitaxel combined with Bevacizumab in HER2 negative metastatic Breast Cancermetastatic Breast CancerJPRN-UMIN000008140Kobe Breast Cancer Oncology Group24
已完成
2 期
Weekly paclitaxel in combination with bevacizumab in patient with HER2 nagative breast cancer who were previously treated with taxane - PhaseIIHER2 negative breast cancerJPRN-UMIN000009582Setouchi Breast Project Comprehensive Support Organization33
已完成
2 期
Weekly Paclitaxel in Combination with Bevacizumab in Patients with Non-Squamous Non-Small Cell Lung Cancer Who Have Failed Previous Treatments-Phase II studyPatients with non-squamous non-small cell lung cancer who have failed previous treatmentsJPRN-UMIN000005608Division of Medical Oncology and Molecular Respirology Department of Multidisciplinary Internal Medicine Faculty of Medicine, Tottori University31
已完成
2 期
Weekly Paclitaxel in Combination with Bevacizumab in Patients with Non-Squamous Non-Small Cell Lung Cancer Previously Untreated -A Phase II studyPatients with non-squamous non-small cell lung cancer previously untreatedJPRN-UMIN000014345Division of Medical Oncology and Molecular Respirology, Faculty of Medicine, Tottori University36